Importance of immunotoxicity in safety assessment: A medical toxicologist's perspective

Toxicology Letters

Volumn 149, Issue 1-3, 2004, Pages 103-108

  Descotes, Jacques ^a  

^a Poison Center   (France)

Author keywords

Clinical immunotoxicology; Immunotoxic effects; Immunotoxicity assessment; Preclinical studies

Indexed keywords

IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ANAPHYLAXIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFERENCE PAPER; DOSE RESPONSE; EXPERIMENTAL MODEL; GRAFT REJECTION; HEREDITY; HUMAN; HYPERSENSITIVITY; IMMUNE FUNCTION TEST; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; INFECTION; LYMPHOID ORGAN; LYMPHOMA; MORBIDITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REDUNDANCY ANALYSIS; RISK ASSESSMENT; SIDE EFFECT; SKIN CANCER; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; RESEARCH DESIGN; SPECIES SPECIFICITY;

ANIMALIA;

EID: 1842666678     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2003.12.024     Document Type: Conference Paper

References (35)

1. Barrons R.W. Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 17:1997;1220-1232.
2. Basketter D.A., Bremmer J.N., Buckley P., Kammüller M.E., Kawabata T., Kimber I., Loveless S.E., Magda S., Stringer D.A., Vohr H.W. Pathology considerations for, and subsequent risk assessment of, chemicals identified as immunosuppressive in routine toxicology. Food Chem. Toxicol. 33:1995;239-243.
3. Burchiel S.W., Lauer F.T., Gurulé D., Mounho B.J., Salas V.M. Use and future applications of flow cytometry in immunotoxicity testing. Methods. 19:1999;28-35.
4. Choquet-Kastylevsky G., Descotes J. Value of animal models for predicting hypersensitivity reactions to medicinal products. Toxicology. 129:1998;27-35.
5. Cooper G.S., Miller F.W., Pandey J.P. The role of genetic factors in autoimmune disease: implications for environmental research. Environ. Health Perspect. 107(Suppl. 5):1999;693-700.
6. CPMP, 2000. Note for Guidance on Repeated Dose Toxicity Testing. CPMP/SWP/1042/99. Document available at http://www.health.gov.au/tga/docs/pdf/ euguide/swp/104299en.pdf.
7. Cunnigham M.L. A mouse is not a rat is not a human: species differences exist. Toxicol. Sci. 70:2002;157-158.
8. Dean J.H. Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. Toxicology. 119:1997;95-101.
9. De Rosa F.G., Bonora S., Di Perri G. Tuberculosis and treatment with infliximab. N. Engl. J. Med. 346:2002;623-626.
10. Descotes J. Autoimmunity and toxicity testing. Toxicol. Lett. 112-113:2000;461-465.
11. Descotes G., Pinard D., Gallas J.F., Penacchio E., Blot C., Moreau C. Extension of the 4-week safety study for detecting immune system impairment appears not necessary: example of cyclosporin A in rats. Toxicology. 112:1996;245-256.
12. Farine J.C. Animal models of autoimmune disease in immunotoxicity assessment. Toxicology. 119:1997;29-35.
13. FDA, 2002. Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs. Document available at http://www.fda.gov/cder/ guidance/4945fnl.pdf.
14. Haley P.J. Species differences in the structure and function of the immune system. Toxicology. 188:2003;49-71.
15. Holsapple M.P. Developmental immunotoxicity testing: a review. Toxicology. 185:2003;193-203.
16. House R.H. Theory and practice of cytokine assessment in immunotoxicology. Methods. 19:1999;17-27.
17. Immunotoxicology Technical Committee, 2001. Application of flow cytometry to immunotoxicity testing: summary of a workshop. Toxicology 163, 39-48.
18. Johnson S.G.O., O'Bourihane J., Bousquet J., Bruijnzeel-Koomen C., Dreborg S., Haahtela T., Kowalski M.L., Mygind N., Ring J., van Cauwenberge P., van Hage-Hamsten M., Wüthrich B. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy. 56:2001;813-824.
19. Kore E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:2002;349-360.
20. Ladics G.S., Smith S., Elliott G.S., Slone T.W., Loveless S.E. Further evaluation of the incorporation of an immunotoxicological function assay for assessing humoral immunity for hazard assessment purposes in rats in a standard toxicology study. Toxicology. 126:1998;137-152.
21. Laschi-Loquerie A., Eyraud A., Morisset D., Sanou A., Tachon P., Veysseyre C., Descotes J. Influence of heavy metals on the resistance of mice toward infection. Immunopharmacol. Immunotoxicol. 9:1987;235-241.
22. Luster M.I., Portier C., Pait D.G., Rosenthal G.J., Germolec D.R., Corsini E., Blaylock B.L., Pollock P., Kouchi Y., Craig W., White K.L., Munson A.E., Comment C.E. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam. Appl. Toxicol. 21:1994;71-82.
23. Moser R., Quesniaux V., Ryffel B. Use of transgenic animals to investigate drug hypersensitivity. Toxicology. 158:2001;75-83.
24. Naisbitt D.J., Pirmohamed M., Park B.K. Immunopharmacology of hypersensitivity reactions to drugs. Curr. Allergy Asthma Rep. 3:2003;22-29.
25. Oshiro Y., Morris D.L. TNF-α release from human peripheral blood mononuclear cells to predict the proinflammatory activity of cytokines and growth factors. J. Pharmacol. Toxicol. Methods. 37:1997;55-59.
26. Pieters R., Ezendam J., Bleumink R., Bol M., Nierkens S. Predictive testing for autoimmunity. Toxicol. Lett. 127:2002;83-91.
27. Powell J.J., Van de Water J., Gershwin M.E. Evidence for the role of environmental agents in the initiation or progression of autoimmune conditions. Environ. Health Perspect. 107(Suppl. 5):1999;667-672.
28. Putman E., Van Loveren H., Bode G., Dean J., Hastings K., Nakamura K., Verdier F., Van der Laan J.W. Assessment of the immunotoxic potential of human pharmaceuticals: a workshop report. Drug Inform. J. 36:2002;417-427.
29. Silverstein A.M. Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat. Immunol. 2:2001;279-281.
30. Singh N., Yu V.L. Infections in organ transplant recipients. Curr. Op. Infect. Dis. 9:1996;223-229.
31. Via C.S., Nguyen P., Niculescu F., Papadimitriou J., Hoover D., Silbergeld E.K. Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. Environ. Health Perspect. 111:2003;1273-1277.
32. Vial T., Descotes J. Immunosuppressive drugs and cancer. Toxicology. 185:2003;229-240.
33. Vial, T., Chevrel, G., Descotes, J., 2000. Drugs acting on the immune system. In: Dukes, M.N.G., Aronson, J.K. (Eds.), Meyler's Side-Effects of Drugs, 14th ed. Elsevier, Amsterdam, pp. 1246-1337.
34. Vos J.G., Van Loveren H. Experimental studies on immunosuppression: how do they predict to man? Toxicology. 129:1998;13-26.
35. Zelikoff, J.T., Cohen, M.D., 1996. Immunotoxicology or inorganic metal compounds. In: Smialowicz, R.J., Holdsapple, M.P. (Eds.) Experimental Immunotoxicology. CRC Press, Boca Raton, pp. 189-228.